ALNY
Alnylam Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Growth
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ALNY
Alnylam Pharmaceuticals, Inc.
A leading RNAi therapeutics company with a pipeline of innovative treatments for rare genetic diseases
675 West Kendall Street, Henri A. Termeer Square Cambridge, MA 02142
--
Alnylam Pharmaceuticals, Inc., a Delaware corporation, was established in May 2003. The company is a biopharmaceutical company developing new treatments based on RNA or RNAi interference. RNAi is a specific gene that selectively silences and regulates expression that occurs naturally in cells in organisms. Since many diseases are caused by inappropriate activities of specific genes, the ability to selectively silence genes through RNAi could provide a new way to treat many human diseases. The company believes that drugs that work through the RNAi principle have the potential to become a new class of drugs, such as small molecule drugs, protein drugs, and antibody drugs. Through the intellectual property rights and expertise that have been established in RNAi, the company is developing a set of biochemical methods to help the company build a system through which it can develop and improve the treatment of RNAi for various diseases.
Earnings Call
Q1/2025
Estimate EPS-0.37
Actual EPS-0.01
Estimate Revenue584.77M
Actual Revenue594.19M
Alnylam Pharmaceuticals' Q1 2025: Unraveling Key Contradictions in AMVUTTRA's Launch and Market Strategy
May 02,2025 12:49
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.13
Actual EPS0.32
Estimate Revenue658.78M
Actual Revenue773.69M
Alnylam Pharmaceuticals' Q2 2025: Unraveling Key Contradictions in AMVUTTRA's Market Strategy and Patient Access
Aug 02,2025 07:43
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ALNY has released its 2025 Q3 earnings. EPS was reported at 2.9, versus the expected 1.75, beating expectations. The chart below visualizes how ALNY has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ALNY has released its 2025 Q3 earnings report, with revenue of 1.25B, reflecting a YoY change of 149.35%, and net profit of 251.08M, showing a YoY change of 325.05%. The Sankey diagram below clearly presents ALNY's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
